Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Weighted Mean00:57

Weighted Mean

While taking the arithmetic, geometric, or harmonic mean of a sample data set, equal importance is assigned to all the data points. However, all the values may not always be equally important in some data sets. An intrinsic bias might make it more important to give more weightage to specific values over others.
For example, consider the number of goals scored in the matches of a tournament. While computing the average number of goals scored in the tournament, it may be more important to...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Decision Making: P-value Method01:09

Decision Making: P-value Method

The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
Expected Frequencies in Goodness-of-Fit Tests01:19

Expected Frequencies in Goodness-of-Fit Tests

A goodness-of-fit test is conducted to determine whether the observed frequency values are statistically similar to the frequencies expected for the dataset. Suppose the expected frequencies for a dataset are equal such as when predicting the frequency of any number appearing when casting a die. In that case, the expected frequency is the ratio of the total number of observations (n) to the number of categories (k).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized Controlled Trial of a Digital Intervention (KidneyTIME) to Promote Live Donor Kidney Transplantation.

Clinical transplantation·2026
Same author

A Novel Method to Apply Race and Ethnicity Observation for Nursing Home Residents Using Multiple Medicare Administrative Datasets.

Medical care·2026
Same author

Problem-solving tools to encourage cancer screening among low health literacy populations in Western New York.

Preventive medicine reports·2026
Same author

Hospital-Level Variation in Transcatheter vs Surgical Aortic Valve Replacement Among Patients Younger Than 65 Years.

The Annals of thoracic surgery·2026
Same author

Balancing fidelity and flexibility: a case study presentation of an augmented dynamic adaptation process for socio-technical innovations in healthcare.

Frontiers in health services·2026
Same author

The Impact of Hospital Mergers: Exploring the Importance of Flagship Designation, Hospital Volume, and Surgeon Volume on Perioperative Outcomes Following Whipple Procedure.

Journal of surgical oncology·2026

Related Experiment Video

Updated: Jul 14, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.

Katia Noyes1, Andrew W Dick, Robert G Holloway

  • 1Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York 14620, USA. katia_noyes@urmc.rochester.edu

Medical Decision Making : an International Journal of the Society for Medical Decision Making
|May 16, 2007
PubMed
Summary

Country-specific EQ-5D weights significantly impact Parkinson disease treatment cost-effectiveness. Using US weights, not UK weights, decreased the likelihood that pramipexole was a cost-effective initial strategy over levodopa.

More Related Videos

Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

Related Experiment Videos

Last Updated: Jul 14, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

Area of Science:

  • Health Economics
  • Clinical Trials
  • Parkinson's Disease Research

Background:

  • Cost-effectiveness (CE) analyses are crucial for healthcare decisions.
  • Parkinson's disease (PD) management involves choices between drugs like pramipexole and levodopa.
  • EQ-5D preference weights vary by country, potentially influencing CE outcomes.

Purpose of the Study:

  • To evaluate how country-specific EQ-5D preference weights affect the cost-effectiveness of initial pramipexole versus levodopa for Parkinson disease.
  • To compare the CE results using UK and US preference weights.

Main Methods:

  • A 4-year randomized trial comparing initial pramipexole and levodopa in 301 PD patients.
  • Health-related quality of life (HRQOL) measured using EQ-5D.
  • Cost-effectiveness calculated using both UK and US preference weights to determine quality-adjusted life-years (QALYs).

Main Results:

  • Using UK weights, pramipexole showed an incremental effectiveness of 0.155 QALYs, with an ICER of $42,989/QALY.
  • Using US weights, incremental effectiveness decreased to 0.062 QALYs, increasing the ICER to $108,498/QALY.
  • The probability of pramipexole being cost-effective was higher with UK weights compared to US weights at all willingness-to-pay thresholds.

Conclusions:

  • Country-specific preference weights significantly influence CE estimates in clinical trials.
  • US preference weights reduced the estimated cost-effectiveness of pramipexole compared to levodopa.
  • This highlights the importance of using relevant, country-specific weights in economic evaluations for Parkinson disease treatments.